Tag: FDA
Lupin Settles Glumetza Case For $150M
Lupin will pay US$150 million to resolve antitrust litigation over its alleged role in a scheme to delay generic versions of the blockbuster diabetes...
US: FDA names drugmakers potentially acting to delay cheap generics
The US Food and Drug Administration (FDA) on Thursday, May 17, listed drugmakers, including Celgene, Johnson & Johnson, Gilead Sciences and Novartis, which the...
Refusal to Deal Under FDA Imposed Risk Evaluation and Mitigation Strategies...
This article is part of a Chronicle. See more from this Chronicle
Robert Maness, Brian Segers, Apr 29, 2014
The Federal Trade Commission, as part of...
Regulation of Information and Advertising
Paul Rubin, Apr 24, 2008
A version of this article was originally prepared for the Encyclopedia of Law and Economics (Edward Elgar, 2nd ed. 2008/2009)....
